Thu, Mar 5, 2015, 3:52 AM EST - U.S. Markets open in 5 hrs 38 mins

Recent

% | $
Quotes you view appear here for quick access.

Myriad Genetics Inc. Message Board

  • ripestocks ripestocks Mar 30, 2010 9:03 PM Flag

    Where is the threat? Please explain!

    MYGN is still a great buy. First, let's look at the facts:
    1) A judge struck down patents on Myriad's BRACAnalysis tests.
    2) 80% of revenues come from BRACAnalysis tests.
    3) Without these patents others can compete with these tests.

    Here is why it is not so gloomy:
    1) 7 patents on the tests were voided. They still have 16 patents on the tests. Sounds like competition will have a much harder time competing. Myriad's CEO said "we do not believe that the final outcome of this litigation will have a material impact on Myriad's operations due to the patent protection afforded Myriad by its remaining patents"
    2) Myriad will certainly appeal which could last years. Companies are unlikely to start developing a competing drug not knowing if the appeal will give the patents right back to Myriad.

    So my question is, what threat does this judgment pose? What warrants a near 5% drop? Please explain! I still stand behind my original analysis and see a buy opportunity as the price drops.

    http://www.ripe-stocks.com/stock-analysis/20

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • this company is full of idiots. what right do they THINK they have to patent a lifeform that occurs in nature. thats just FOOKIN absurd!!!! Greedy f.ucks, Im glad they were struck down in court. Jesus when does corporate profit stop in medicine???

    • not only will they appeal but i think they will win the appeal easily. This judge seems to think that genes are simply discovered. The discovery methods are,however,inventions. I think the patent office will defend their issuance. Moreover, the entire biotech industry would be threatened by disallowance of patents.

      • 1 Reply to ziggy1230072004
      • What is the likelihood that every claim of every DNA patent would eventually be disallowed?

        Even if DNA patents are narrowed in scope, the genetic diagnostic business still represents huge opportunities. Factors such as first mover advantages, brand positioning/loyalty and perceived switching costs would become more important as competition would be made easier. Companies would just have to become more creative at serving their customers like in most other industries.

 
MYGN
34.30+0.38(+1.12%)Mar 4 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.